[breadcrumb_custom]

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX): The Stock For Success Over The Next Few Months

In the last trading session, 5.45 million Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares changed hands as the company’s beta touched 1.93. With the company’s per share price at $5.95 changed hands at $0.1 or 1.71% during last session, the market valuation stood at $1.22B. BCRX’s last price was a discount, traded about -75.29% off its 52-week high of $10.43. The share price had its 52-week low at $4.82, which suggests the last value was 18.99% up since then. When we look at Biocryst Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 2.79 million shares, with the 3-month average coming to 1.41.

Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information

Instantly BCRX was in green as seen at the end of in last trading. With action 15.76%, the performance over the past five days has been green. The jump to weekly highs of 6.35 added 1.71% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.67%, with the 5-day performance at 15.76% in the green. However, in the 30-day time frame, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) is -8.04% down. Looking at the short shares, we see there were 29.04 million shares sold at short interest cover period of 8.25 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts

Data shows that the Biocryst Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -14.63% over the past 6 months, a 18.80% in annual growth rate that is considerably higher than the industry average of 11.60%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Biocryst Pharmaceuticals Inc. will rise 36.80%, while the growth in revenue is estimated to hit 21.40% for the next quarter. Year-over-year growth is forecast to reach 21.00% up from the last financial year.

Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of $90.01 million. 6 analysts are of the opinion that Biocryst Pharmaceuticals Inc.’s revenue for the quarter ending Mar 2024 will be $87.65 million. The company’s revenue for the corresponding quarters a year ago was $79.55 million and $68.78 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 13.20%. The estimates for the next quarter sales put growth at 27.40%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.25%. The 2024 estimates are for Biocryst Pharmaceuticals Inc. earnings to increase by 21.00%, but the outlook for the next 5-year period is at 44.80% per year.

BCRX Dividends

Biocryst Pharmaceuticals Inc. is expected to release its next quarterly earnings report between February 19 and February 23.

On Key

Related Posts